10月8日晚间，百济神州发布公告，披露旗下核心BTK抑制剂泽布替尼（商品名"百悦泽"）在美国市场 被诉专利侵权的最新进展：百济神州及艾伯维旗下公司Pharmacyclics公司已向法院提交一份共同协议， 自愿撤回案件，案件已做出终局处理。这意味着，这场历时两年多的跨国专利侵权诉讼案，百济神州获 胜。 尽管双方就上述专利侵权案已经终结，但艾伯维针对百济神州BGB-16673的专利诉讼仍在进行中。2024 年9月，艾伯维提起诉讼，声称百济神州在BTK降解剂研发过程中窃取了艾伯维的商业机密，该诉讼主 要围绕百济神州在研药物BGB-16673。百济神州认为，该诉讼意在阻碍BGB-16673的开发进程。BGB- 16673是一款口服、靶向BTK的在研嵌合式降解激活化合物（CDAC），也是百济神州管线中进展最快 的BTK降解剂，2024年8月27日被FDA授予快速通道认定。 对于这一起诉讼，百济神州表示，无论结果是否对公司有利，对此类申诉进行辩护可能会导致高额成 本，并分散管理层的注意力。如果公司未能抗辩成功，可能导致需要支付经济赔偿以及失去重要的知识 产权并遭受声誉损失。 畅销药的专利保护战 泽布替尼被诉专利侵权，百济 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年9月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百三十七名承授人授 出涉及合共36,234股美國存託股份的受限制股份單位，並向一名承授人授出涉及 合共2,935股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的受限制股份單位及業績股份單位 於2025年9月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 三十七名承授人合共36,234股美國存託股份受限制股份單位，並向一名承授人授 出合共2,935股美國存託股份業績股份單位。該等受限制股份單位及業績股份單位 相當於509,197股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年10月8日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | ...

Core Viewpoint - The majority of Chinese concept stocks in the US pre-market are experiencing declines, with notable exceptions such as Bilibili which is up by 6% [1] Company Performance - Bilibili is showing a positive performance with a 6% increase [1] - JD.com is slightly down by 0.2% [1] - NIO has decreased by 0.5% [1] - Li Auto and Alibaba both fell by 1% [1] - Xpeng Motors is down by 3% [1] - BeiGene has seen a decline of 4% [1]

Group 1 - Norin Pharma and Zenas BioPharma have reached a licensing agreement for the global development and commercialization rights of Obinutuzumab in multiple sclerosis and other non-oncology indications [1] - Zenas also acquired rights to two preclinical molecules, a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor [1] - This strategic collaboration aims to accelerate the clinical development of Obinutuzumab and maximize its clinical and commercial value globally, particularly in the field of multiple sclerosis [1] Group 2 - The board of *ST Sailong has received resignation letters from Chairman Chen Ke, Vice President and Secretary Zhang Xu, and Vice President Duan Daifeng [2] - Chen Ke and Zhang Xu will retain their positions as President and Secretary, respectively, while Duan Daifeng's resignation reflects a personal career development decision [2] - This "name resignation but actual retention" adjustment is common but may indicate potential strategic disagreements within the company [2] Group 3 - BeiGene announced that Pharmacyclics LLC has decided not to appeal the final written decision of the U.S. Patent and Trademark Office, leading to the voluntary withdrawal of the lawsuit [3] - The lawsuit was resolved without adverse effects on BeiGene, and the development and sales of Baiyueze® in the U.S. remain unaffected [3] - The resolution of this litigation does not pose significant negative impacts on the company's operations [3] Group 4 - BaiLi Tianheng's first antibody-drug conjugate (ARC) has received clinical trial approval from the National Medical Products Administration [4] - The drug, Lutetium [177Lu]-BL-ARC001 injection, is intended for patients with locally advanced or metastatic solid tumors who have failed standard treatments [4] - This therapy offers new hope for advanced solid tumor patients by precisely targeting and destroying tumor cells, showcasing a differentiated innovation path in the current ADC drug development landscape [4]

Core Viewpoint - The lawsuit involving BeiGene and Pharmacyclics has been voluntarily withdrawn, resulting in no negative impact on the company's operations or product development in the U.S. market [2][5][4]. Group 1: Lawsuit Details - On June 13, 2023, Pharmacyclics LLC filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming patent infringement related to the product 百悦泽? [3]. - The patent in question is U.S. Patent No. 11,672,803, which was granted to Pharmacyclics on the same day the lawsuit was filed [3]. - The court has agreed to pause the infringement lawsuit pending the outcome of a Patent Trial and Appeal Board (PTAB) review, which is expected to conclude by November 1, 2023 [3]. Group 2: Impact on the Company - The lawsuit has not adversely affected the research and sales of 百悦泽? in the U.S. market, nor has it significantly impacted the company's overall operations [5]. - The company maintains confidence in its intellectual property related to 百悦泽? and plans to continue developing innovative cancer treatment solutions [2][5].

Core Points - BeiGene announced the grant of a total of 36,000 restricted stock units to 237 grantees under the 2016 option and incentive plan [1] - Additionally, one grantee was awarded a total of 2,935 performance stock units [1] - The total restricted stock units and performance stock units correspond to 509,197 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Points - BeiGene (06160) announced that on September 30, 2025, the Board's Compensation Committee granted a total of 36,000 restricted stock units involving American Depositary Shares to 237 grantees under the 2016 Option and Incentive Plan [1] - Additionally, one grantee was awarded 2,935 performance stock units involving American Depositary Shares [1]

Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units and performance stock units to 237 recipients, totaling 36,000 American Depositary Shares (ADS) [1] Summary by Categories - **Stock Grants** - The board's compensation committee granted a total of 36,000 restricted stock units to 237 recipients [1] - Additionally, one recipient was awarded 2,935 performance stock units [1] - **Equity Impact** - The restricted stock units and performance stock units correspond to 509,197 shares, which represents approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - BeiGene (06160) announced the grant of restricted stock units and performance stock units to its employees as part of its 2016 option and incentive plan, indicating ongoing commitment to employee incentives and retention [1] Summary by Categories Company Actions - The board's compensation committee granted a total of 36,000 American Depositary Shares (ADS) in restricted stock units to 237 grantees [1] - Additionally, one grantee received 2,935 ADS in performance stock units [1]